228 related articles for article (PubMed ID: 9217190)
21. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
22. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Detrait MY; Morisset S; Peffault de Latour R; Yakoub-Agha I; Crocchiolo R; Tabrizi R; Bay JO; Chevalier P; Barraco F; Raus N; Vigouroux S; Magro L; Mohty M; Milpied N; Blaise D; Socié G; Michallet M
Bone Marrow Transplant; 2015 Feb; 50(2):253-8. PubMed ID: 25365068
[TBL] [Abstract][Full Text] [Related]
23. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
24. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
[TBL] [Abstract][Full Text] [Related]
25. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
[TBL] [Abstract][Full Text] [Related]
27. Graft versus host disease in allogeneic stem cell transplantation--3 1/2 years experience.
Hashmi K; Khan B; Ahmed P; Hussain I; Altaf C; Raza S; Iqbal H; Khan MA; Malik HS; Naeem M; Kamal K; Anwar M
J Pak Med Assoc; 2005 Oct; 55(10):423-7. PubMed ID: 16304849
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M
Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648
[TBL] [Abstract][Full Text] [Related]
29. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options.
Wiesmann A; Pereira P; Böhm P; Faul C; Kanz L; Einsele H
Bone Marrow Transplant; 1998 Sep; 22(6):565-9. PubMed ID: 9758344
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse.
Cavazzana-Calvo M; Bordigoni P; Michel G; Esperou H; Souillet G; Leblanc T; Stephan JL; Vannier JP; Mechinaud F; Reiffers J; Vilmer E; Landman-Parker J; Benkerrou M; Baruchel A; Pico J; Bernaudin F; Bergeron C; Plouvier E; Thomas C; Wijdenes J; Lacour B; Blanche S; Fischer A
Br J Haematol; 1996 Apr; 93(1):131-8. PubMed ID: 8611446
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
32. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
33. Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation.
Vargas-Díez E; Fernández-Herrera J; Marin A; Cámara R; García-Díez A
Br J Dermatol; 2003 Jun; 148(6):1129-34. PubMed ID: 12828739
[TBL] [Abstract][Full Text] [Related]
34. Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran.
Saddadi F; Najafi I; Hakemi MS; Falaknazi K; Attari F; Bahar B
Iran J Kidney Dis; 2010 Jan; 4(1):20-6. PubMed ID: 20081300
[TBL] [Abstract][Full Text] [Related]
35. The role of adenotonsillectomy in graft-versus-host disease.
Schwab B; Raynor E
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):57-60. PubMed ID: 22018926
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Gluckman E; Esperou-Bourdeau H; Reiffers J; Pico JL; Bordigoni P; Thuret I; Blaise D; Bernaudin F; Jouet JP
J Clin Oncol; 1994 Jun; 12(6):1217-22. PubMed ID: 8201385
[TBL] [Abstract][Full Text] [Related]
37. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
[TBL] [Abstract][Full Text] [Related]
39. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
Hernández-Boluda JC; Marín P; Carreras E; Aguilar JL; Grañena A; Rozman C; Montserrat E
Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
